On June 28, 2021 Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, reported that it has entered into an agreement to transfer the rights for the commercialization of Apealea (paclitaxel micellar) in the Nordics and Baltics to Inceptua Group (‘Inceptua’), effective immediately (Press release, Oasmia, JUN 28, 2021, View Source [SID1234584390]). Inceptua already has exclusive rights for the commercialization of Apealea in the rest of Europe, following an agreement signed with Oasmia’s global strategic partner for Apealea, Elevar Therapeutics, Inc. in 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Apealea is approved by the European regulatory authorities for use in combination with carboplatin for the treatment of adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer. Under the terms, Inceptua now possesses the rights to commercialize Apealea throughout the whole of Europe. Oasmia will be eligible for double-digit royalties on sales.

François Martelet, M.D., CEO of Oasmia, commented: "This agreement allows Oasmia to continue streamlining operations as we focus on expanding our oncology development pipeline. Elevar has selected Inceptua as they are an ideal partner for Apealea in the Nordics and Baltics and in the best position to make a success of commercializing Apealea in Europe, with strong capabilities and suitable infrastructure."